Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yonghe Medical Group CoSTU:L97 -5.97%84 Debt-to-EBITDA is 1.78 as of Jun. 2026, which is 16% below its 10-year median of 2.11. GuruFocus rates STU:L97 with a GF Score™ of 84/100 and a GF Value™ of €0.20. The stock has 7 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Yonghe Medical Group Co ranks worse than 61.3% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Yonghe Medical Group Co's Debt-to-EBITDA or its related term are showing as below:
STU:L97'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.58 Med: 2.11 Max: 6.6
Current: 2.08
During the past 8 years, the highest Debt-to-EBITDA Ratio of Yonghe Medical Group Co was 6.60. The lowest was -5.58. And the median was 2.11.
STU:L97's Debt-to-EBITDA is ranked worse than 61.3% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs STU:L97: 2.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Yonghe Medical Group Co Debt-to-EBITDA Related Terms
Yonghe Medical Group Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L97 vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Yonghe Medical Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yonghe Medical Group Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yonghe Medical Group Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Yonghe Medical Group Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Yonghe Medical Group Co (STU:L97) has a Debt-to-EBITDA of 1.78 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Yonghe Medical Group Co. This is 16% below median its historical median of 2.11. According to the industry distribution chart, Yonghe Medical Group Co ranks #293 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 61.3%.
Is Yonghe Medical Group Co's Debt-to-EBITDA too high?
Yonghe Medical Group Co's current Debt-to-EBITDA of 1.78 is 16% below median its 10-year median of 2.11. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Yonghe Medical Group Co's value of 1.78 is 18.9% below this industry median. Based on the distribution chart, Yonghe Medical Group Co ranks #293 out of 478 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Yonghe Medical Group Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Yonghe Medical Group Co's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Yonghe Medical Group Co ranks #293 out of 478 companies for Debt-to-EBITDA. This places Yonghe Medical Group Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. Yonghe Medical Group Co's value of 1.78 is 18.9% below this benchmark. While the company's 10-year median is 2.11 vs. the industry median of 2.20, Yonghe Medical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yonghe Medical Group Co's current Debt-to-EBITDA of 1.78 is 18.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Yonghe Medical Group Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yonghe Medical Group Co's current Debt-to-EBITDA is 1.78, which is 16% below median its own 10-year median of 2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yonghe Medical Group Co stock overvalued right now?
Yonghe Medical Group Co (STU:L97) has a current Debt-to-EBITDA of 1.78. The stock's GF Value™ is €0.20, compared to a current price of €0.25 — trading 26% above its estimated fair value. The current Debt-to-EBITDA is 1.78, which is 16% below median its 10-year median of 2.11 and 18.9% below the Healthcare Providers & Services industry median of 2.20. Yonghe Medical Group Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Yonghe Medical Group Co (STU:L97), the current Debt-to-EBITDA is 1.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yonghe Medical Group Co (STU:L97) Overvalued in 2026?
Based on GuruFocus' analysis, Yonghe Medical Group Co stock appears to be overvalued.
The current stock price of €0.25 is trading 26% above its estimated GF Value™ of €0.20.
Key valuation signals for STU:L97:
Debt-to-EBITDA: 1.78 (16% below median its 10-year median of 2.11)
GF Value™: €0.20 vs. price of €0.25 (26% above fair value)
Industry Position: 18.9% below the Healthcare Providers & Services median (#293 of 478)
No single metric tells the full story. See the STU:L97 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yonghe Medical Group Co Ltd is a medical group in China that specializes in providing hair-related healthcare services. The company is principally engaged in the provision of hair transplant services. The company generated the majority of its revenue from hair transplant services. The company offers one-stop hair-related healthcare services covering hair transplants, medical hair care, routine hair restoration, and other ancillary services.
84GF Score
Get the complete analysis for STU:L97
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L97 has been successfully added to your 
